FULC Fulcrum Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FULC

Price (delayed)

$7.75

Market cap

$480M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.59

Enterprise value

$464.16M

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine ...

Highlights
The company's EPS rose by 35% YoY and by 3.6% QoQ
The debt has contracted by 19% YoY and by 6% from the previous quarter
Fulcrum Therapeutics's gross profit has plunged by 56% YoY but it has increased by 7% from the previous quarter
The revenue has plunged by 56% YoY but it has grown by 7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fulcrumtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of FULC
Market
Shares outstanding
61.94M
Market cap
$480M
Enterprise value
$464.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.04
Price to sales (P/S)
169.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
165.48
Earnings
Revenue
$2.81M
EBIT
-$97.34M
EBITDA
-$95.16M
Free cash flow
-$91.47M
Per share
EPS
-$1.59
Free cash flow per share
-$1.49
Book value per share
$3.8
Revenue per share
$0.05
TBVPS
$4.2
Balance sheet
Total assets
$257.69M
Total liabilities
$22.5M
Debt
$10.82M
Equity
$235.19M
Working capital
$228.52M
Liquidity
Debt to equity
0.05
Current ratio
17.71
Quick ratio
17.39
Net debt/EBITDA
0.17
Margins
EBITDA margin
-3,392.6%
Gross margin
100%
Net margin
-3,470.1%
Operating margin
-3,945.2%
Efficiency
Return on assets
-33.6%
Return on equity
-36.6%
Return on invested capital
-38.2%
Return on capital employed
-39.9%
Return on sales
-3,470.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FULC stock price

How has the Fulcrum Therapeutics stock price performed over time
Intraday
1.31%
1 week
8.54%
1 month
-15.12%
1 year
164.51%
YTD
14.81%
QTD
-17.9%

Financial performance

How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$2.81M
Gross profit
$2.81M
Operating income
-$110.66M
Net income
-$97.34M
Gross margin
100%
Net margin
-3,470.1%
Fulcrum Therapeutics's operating margin has plunged by 122% YoY but it has increased by 7% from the previous quarter
The net margin has plunged by 100% YoY but it has grown by 8% from the previous quarter
Fulcrum Therapeutics's gross profit has plunged by 56% YoY but it has increased by 7% from the previous quarter
The revenue has plunged by 56% YoY but it has grown by 7% from the previous quarter

Growth

What is Fulcrum Therapeutics's growth rate over time

Valuation

What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
2.04
P/S
169.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
165.48
The company's EPS rose by 35% YoY and by 3.6% QoQ
FULC's P/B is 104% above its last 4 quarters average of 1.0 but 22% below its 5-year quarterly average of 2.6
The equity has grown by 18% YoY but it has contracted by 8% from the previous quarter
The price to sales (P/S) is 115% higher than the 5-year quarterly average of 78.7 and 87% higher than the last 4 quarters average of 90.4
The revenue has plunged by 56% YoY but it has grown by 7% from the previous quarter

Efficiency

How efficient is Fulcrum Therapeutics business performance
The company's return on sales has shrunk by 100% YoY but it rose by 8% QoQ
FULC's return on invested capital is up by 42% year-on-year and by 5% since the previous quarter
Fulcrum Therapeutics's ROE has increased by 36% YoY and by 4.9% from the previous quarter
Fulcrum Therapeutics's ROA has increased by 32% YoY and by 4% from the previous quarter

Dividends

What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FULC.

Financial health

How did Fulcrum Therapeutics financials performed over time
The current ratio has grown by 43% year-on-year but it has declined by 5% since the previous quarter
Fulcrum Therapeutics's quick ratio has increased by 42% YoY but it has decreased by 5% from the previous quarter
The debt is 95% less than the equity
The debt to equity is down by 29% year-on-year but it is up by 25% since the previous quarter
The debt has contracted by 19% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.